Finding a new medicine is never easy. But developing treatments for patients with rare diseases — conditions that afflict fewer than 200,000 people in the United States — is particularly challenging.
Repurposing and repositioning have gained considerable attention from a range of stakeholders, including NIH, academic institutions, pharmaceutical companies, and even some technology companies, for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results